Feb 12, 2025
Diamyd Medical announces expanded financial support from Breakthrough T1D
Jan 13, 2025
Diamyd Medical updates U.S. market potential for Diamyd®
Jan 10, 2025
Diamyd Medical confirms key advances toward Accelerated Approval for Diamyd® following FDA Type C Meeting
Dec 13, 2024
Diamyd Medical Aligns with FDA on Key Elements for an Accelerated Approval Process
Nov 06, 2024
In-depth analysis showing robust Diamyd® treatment effects across clinical trials to be shared at the 2024 IDS Diabetes Congress
Jul 18, 2024
Diamyd Medical receives second U.S. FDA Fast Track designation for Diamyd® - for the prevention of Type 1 Diabetes
Feb 15, 2024
Diamyd Medical receives U.S. FDA Fast Track designation for Diamyd®
Jan 08, 2024
Diamyd Medical gains market research findings to guide U.S. commercial strategy
Dec 16, 2020
Diamyd Medical and Critical Path Institute announce data sharing collaboration to develop advanced drug development tools in type 1 diabetes
Sep 16, 2020
Diamyd Medical invites to a webcast presentation on September 17 on the results from DIAGNODE-2
Aug 05, 2020
Diabetologia publishes results highlighting efficacy of the diabetes vaccine Diamyd® in genetically defined subgroups of type 1 diabetes
Jun 24, 2020
Diamyd Medical AB (publ) Quarterly Report III 19/20 -September 2019 - May 2020, Fiscal year 2019/2020
May 04, 2020
Promising Findings From the First Part of a Clinical Trial With Remygen®
Apr 24, 2020
Japan Grants Patent for Intralymphatic Administration of the Diabetes Vaccine Diamyd®
Dec 12, 2019
Significant Effect of Diamyd® in Type 1 Diabetes Shown in a New Comprehensive Analysis of Previous Phase III and Phase II Trials
Oct 15, 2019
Diamyd Medical Enters Agreement for Intralymphatic Diamyd ® Trial in LADA
Sep 09, 2019
Feasibility Study Supports the use of Intralymphatic Injections of Diamyd®
Jun 04, 2019
New Interim Report at 30 Months and After Extra Injection Supports Long-term Effect of Intralymphatic Diamyd®
May 29, 2019
The Swedish Medical Products Agency Approves New Treatment Arm With Remygen® and Alprazolam in Phase I/II Trial ReGenerate-1
Mar 26, 2019
Diamyd Medical Announces Strategic Activities for 2019 and 2020